Armenia
Tuberculosis profile
| High MDR-TB burden |
Population  2013 3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.17 (0.14–0.2) 5.7 (4.8–6.7)
Mortality (HIV+TB only) 0.012 (<0.01–0.015) 0.4 (0.3–0.52)
Prevalence  (includes HIV+TB) 2 (0.93–3.4) 66 (31–115)
Incidence  (includes HIV+TB) 1.5 (1.3–1.7) 49 (45–57)
Incidence (HIV+TB only) 0.066 (0.06–0.072) 2.2 (2–2.4)
Case detection, all forms (%) 95 (83–100)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 9.4 (7–12) 43 (38–49)
MDR-TB cases among notified pulmonary
TB cases
75 (56–100) 120 (100–130)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 395   62
Pulmonary, clinically diagnosed 408   186
Extrapulmonary 250   96
       
Total new and relapse 1 397    
Previously treated, excluding relapses 20    
Total cases notified 1 417    
Among 1 397 new and relapse cases:
42 (3%) cases aged under 15 years; male:female ratio: 3.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 394 (100%) 73 (20%) 467
Laboratory-confirmed RR-/MDR-TB cases     119
Patients started on MDR-TB treatment     119
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 417 (100)
HIV-positive TB patients 67 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 48 (72)
HIV-positive TB patients on antiretroviral therapy (ART) 48 (72)
HIV-positive people screened for TB 233  
HIV-positive people provided with IPT 0  
Treatment success rate (%)
New and relapse cases registered in 2012 81
Previously treated cases, excluding relapse, registered in 2012 47
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 50
XDR-TB cases started on second-line treatment in 2011 50
Laboratories 2013  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 1.7
Drug susceptibility testing (per 5 million population) 1.7
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 6.2
% Funded domestically 55%
% Funded internationally 45%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-02 Data: www.who.int/tb/data